Switching to amisulpride

Current Medical Research and Opinion

Volumn 18, Issue SUPPL. 3, 2002, Pages

  Peuskens, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

affective symptoms; amisulpride; clozapine; cognitive impairment; compliance; negative symptoms; positive symptoms; quality of life; refractory; relapse; risperidone; side effects

Indexed keywords

DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

CLINICAL PRACTICE; HUMAN; PATIENT CARE PLANNING; PRACTICE GUIDELINE; REVIEW; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT CARE PLANNING; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SCHIZOPHRENIA; SULPIRIDE;

EID: 0036361848     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/030079902125001092     Document Type: Article

References (30)

1. McEvoy JP, Scheifler PL, Frances A (eds). The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry 1999;60(Suppl 11):3-80
2. Sarfati Y, Olivier V, Bouhassira M. New antipsychotics in the treatment of schizophrenia. A European survey. Encephale 1999;25:658-66
3. Weiden PJ, Aquila R, Dalheim L, Standard JM. Switching antipsychotic medications. J Clin Psychiatry 1997; 58(Suppl 10):63-72
4. Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 1995;52:173-88
5. Gardos G, Cole JO, Tarsy D. Withdrawal syndromes associated with antipsychotic drugs. Am J Psychiatry 1978; 135:1321-4
6. Dilsaver SC, Alessi NE. Antipsychotic withdrawal symptoms: phenomenology and pathophysiology. Acta Psychiatr Scand 1988;77:241-6
7. Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980; 137:1395-8
8. Sramek J, Herrera J, Costa J, et al. Persistence of plasma neuroleptic levels after drug discontinuation. J Clin Psychopharmacol 1987;7:436-7
9. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41: 1030-5
10. Glazer W, Herz MI, Mirza M, Mostert M, Hafez H. Treating prodromal episodes to prevent relapse in schizophrenia. Br J Psychiatry 1989;5(Suppl.):123-7
11. Dixon L, Thaker G, Conley R, et al. Changes in psycho-pathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res 1993;10:267-71
12. Spivak B, Weizman A., Wolovick L, Hermesh H, Tyano S, Munitz H. Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. Acta Psychiatr Scand 1990;81:168-9
13. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999;35(Suppl 1):S61-6
14. Mant, TGK, Spector RG. Phase I studies and pharmaco-kinetics. In: Lloyd J, Raven A, eds. Handbook of Clinical Research, 2nd edn. Churchill Medical Communications, 1994
15. Taylor D. Switching from typical to atypical anti-psychotics. CNS Drugs 1997;8:285-92
16. Borison RL. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clin Ther 1996;18:592-607
17. Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54: 49-55
18. Gillet G, Dormerque L, Canal M, Thenot JP. Amisulpride does not inhibit cytochrome P450 isoenzymes. Eur Neuropsychopharmacol 2000;10(Suppl 3):S331-2
19. Colonna L, Saleem P, et al. Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 2000;15:13-22
20. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68-72
21. Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22
22. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999;156:610-16
23. Paillière-Martinot ML, Lecrubier Y, Martinot JL, Aubin F. Improvement of some schizophrenic deficit syndromes with low doses of amisulpride. Am J Psychiatry 1995;152: 130-3
24. Rein W, Fleurot O, Turjanski S. Amisulpride improves affective symptoms in acute schizophrenia. In: Abstracts of the XIth Congress of the European College of Neuro-psychopharmacology, Paris, France, 31 October-4 November 1998. Eur Neuropsychopharmacol 8(Suppl 2):S231
25. ®): a review of 11 clinical studies. Int Clin Psycho-pharmacol 1999;14:209-18
26. Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88: 107-17
27. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997;280:83-97
28. 3) as a target for neuroleptics. Nature (Lond) 1990;347:146-51
29. 3 dopamine receptor antagonistic activity and limbic selectivity. J Pharmacol Exp Ther 1997;280:73-82
30. Levy E, Olié JP, Spiesser J. Impact of amisulpride on health care resources in schizophrenia: preliminary results of a French study. Eur Psychiatry 2000;15(Suppl 2):345